SKYX Platforms Corp. reported fiscal year ended December 31, 2025 results: revenue $92.0 million.
“SKYX reports record sales $92.0 million in 2025 compared with $86 million in 2024.”
Earnings Releases
Quarterly and annual results disclosed under 8-K Item 2.02.
SKYX Platforms Corp. reported Q4 2025 results: revenue $25 million.
“Generated a record $25 million in revenue in Q-4 2025 compared to $24 million in Q-4 2024.”
DBV Technologies S.A. reported the fiscal year ended December 31, 2025 results: net income $147.0 million, EPS $1.05.
“Net loss was $147.0 million for the year ended December 31, 2025, compared to $113.9 million for the year ended December 31, 2024. Net loss per share (based on the weighted average number of shares outstanding over the period) was $1.05 and $1.17 for the year ended December 31, 2025 and 2024, respectively.”
Veritone, Inc. reported FY 2026 results: revenue $130 million - $145 million, net income $22.5 million - $13.5 million. Guidance initiated.
“FY 2026 outlook of Revenue of $130 million - $145 million and Non-GAAP Net Loss of $22.5 million - $13.5 million”
Veritone, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $18.1 million - $30.0 million, net income $37.0 million - $25.1 million.
“Q4 preliminary Revenue in the range of $18.1 million - $30.0 million* - – Q4 preliminary, unaudited GAAP net loss from continuing operations of $37.0 million - $25.1 million;”
LeonaBio, Inc. reported financial results for the year ended December 31, 2025.
“On March 26, 2025, LeonaBio, Inc. (the “Company”) issued a press release reporting its financial results for the year ended December 31, 2025.”
MetaVia Inc. reported financial results for the year ended December 31, 2025.
“On March 26, 2026, MetaVia Inc. issued a press release announcing its financial results for the year ended December 31, 2025 and providing a corporate update.”
Laird Superfood, Inc. reported the fourth quarter and fiscal year ended December 31, 2025 results: revenue $49.9 million.
“99.1) --- EX-99.1 2 ex_892836.htm EXHIBIT 99.1 ex_892836.htm Exhibit 99.1 Laird Superfood Reports Fourth Quarter and Fiscal Year 2025 Financial Results Record Net Sales of $49.9 million for Fiscal Year 2025, growth of 15% year-over-year. Boulder, Colorado – March 26, 2026 – Laird Superfood, Inc. (NYSE American: LSF) (“Laird Superfood,” the “Company”, “we”, and”
Alpha Cognition Inc. reported the year ended December 31, 2025 results: revenue $10.2 million, net income $20.7 million.
“Full Year Fiscal 2025 Financial Results ● Revenues: ZUNVEYL net product revenues were $6.8 million, and licensing revenue totaled $3.4 million, for a combined total of $10.2 million for the year ended December 31, 2025. ● Research & Development: Expenses were $1.9 million, compared to $3.9 million for fiscal year 2024 as the Company transitioned to commercial stage. ● Selling, General & Administrative : Expenses were $29.1 million, up from $8.0 million in 2024, reflecting increased commercial investment in personnel and infrastructure. ● Operating Loss: $22.7 million, compared to $12.0 million in 2024. ● Net Loss: $20.7 million, compared to $14.8 million in 2024.”
Alpha Cognition Inc. reported the fourth quarter ended December 31, 2025 results: revenue $2.5 million.
“Net ZUNVEYL Revenue: Generated approximately $2.5 million in net product revenue in the fourth quarter of 2025.”
Quoin Pharmaceuticals, Ltd. reported financial results for fourth quarter and fiscal year 2025.
“Quoin Pharmaceuticals Ltd. (the "Company") announced its fourth quarter and fiscal year 2025 financial results. A copy of the Company's press release is attached as Exhibit 99.1 hereto and incorporated by reference herein.”
Aptevo Therapeutics Inc. reported financial results for the year ended December 31, 2025.
“On March 26, 2026, Aptevo Therapeutics Inc. (the “Company”) issued a press release announcing its financial results for the period ended December 31, 2025.”
HYPERION DEFI, INC. reported financial results for the fiscal year ended December 31, 2025.
“On March 26, 2026, Hyperion DeFi, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal year ended December 31, 2025.”
LB PHARMACEUTICALS INC reported financial results for fourth quarter and full year ended December 31, 2025.
“On March 26, 2026, LB Pharmaceuticals Inc (the “Company”) issued a press release announcing its financial results for the three months and full year ended December 31, 2025.”
Spero Therapeutics, Inc. reported the year ended December 31, 2025 results: revenue $66.8 million, net income $8.6 million, EPS $0.15.
“fourth quarter of 2025 was primarily due to an increase in collaboration revenue from our agreements with GSK and Pfizer. Total revenue for the year ended December 31, 2025, was $66.8 million, compared to $48.0 million for the year ended December 31, 2024. The revenue increase for the year was primarily due to the aforementioned collaboration revenue related to our”
Spero Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2025 results: revenue $41.3 million, net income $31.5 million, EPS $0.53.
“diluted net gain per share of common stock of $0.15 and a diluted net loss per share of common stock of $(1.27), respectively. • Total revenue for the fourth quarter of 2025 was $41.3 million, compared to total revenue of $15.0 million for the fourth quarter of 2024. The revenue increase for the fourth quarter of 2025 was primarily due to an increase in collaboration”
Lovesac Co reported the fourth quarter and fiscal year 2026, which ended February 1, 2026 results: revenue $248.0 million, net income $32.1 million, EPS $2.19 per share.
“specific reference in that filing. --- EX-99.1 (EX-99.1) --- THE LOVESAC COMPANY REPORTS FOURTH QUARTER AND FISCAL 2026 FINANCIAL RESULTS Q4 FY26 Net Sales Increased 2.7% to $248.0 million vs. Q4 FY25 FY26 Net Sales Increased 2.4% to $697.1 million vs. FY25 Announces New $40 million Share Repurchase Authorization STAMFORD, Co nn., March 26, 2026 (GLOBE NEWSWIRE) --”
WRAP TECHNOLOGIES, INC. reported fourth quarter and full year ended December 31, 2025 results: revenue $1.4 million, net income $(3.9) million.
“operating efficiency as the Company targets approximately 100% revenue growth in 2026. Fourth Quarter 2025 Financial Highlights (vs. Q4 2024): ● Gross revenue increased 62% to $1.4 million, compared to $0.9 million in the prior-year period ● Product sales more than doubled to $1.2 million, compared to $0.6 million in the prior-year quarter, driven by increased”
Zentalis Pharmaceuticals, Inc. reported financial results for the year ended December 31, 2025.
“On March 26, 2026, Zentalis Pharmaceuticals, Inc. (the “Company”) announced its financial results for the year ended December 31, 2025, and commented on certain business updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Current Report") and is incorporated herein by reference.”
MeiraGTx Holdings plc reported financial results for the year ended December 31, 2025.
“On March 26, 2026, the Company issued a press release announcing its financial results for the year ended December 31, 2025.”
Inhibikase Therapeutics, Inc. reported year ended December 31, 2025 results: net income $48.3 million, EPS $0.49 per share.
“Net loss for the year ended December 31, 2025, was $48.3 million, or $0.49 per share, compared to a net loss of $27.5 million, or $1.16 per share in the year ended December 31, 2024.”
MapLight Therapeutics, Inc. reported the full year 2025 results: net income $161.2 million.
“For the full year 2025, net loss was $161.2 million, as compared to $77.6 million for the full year 2024.”
MapLight Therapeutics, Inc. reported the fourth quarter of 2025 results: net income $79.5 million.
“Net loss was $79.5 million for the fourth quarter of 2025, as compared to $21.2 million for the prior year period.”
SpyGlass Pharma, Inc. reported financial results for fourth quarter and fiscal year ended December 31, 2025.
“On March 26, 2026, SpyGlass Pharma, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2025.”
Lucid Diagnostics Inc. reported fourth quarter and full year ended December 31, 2025 results: revenue $1.5 million, net income approximately $16.3 million or $(0.12) per common share, EPS $(0.12) per common share.
“--- Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results Processed 3,664 EsoGuard ® tests and recognized 4Q25 revenue of $1.5 million Expanded EsoGuard access with U.S. Department of Veterans Affairs contract award and strengthened clinical evidence with positive data from the largest reported real-world”
Gain Therapeutics, Inc. reported year ended December 31, 2025 results: net income Net loss for the year ended December 31, 2025, was $20.2 million, or $0.61 per share, basic and diluted, EPS $0.61 per share, basic and diluted.
“Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update BETHESDA, MD, March 26, 2026 -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the fourth quarter and year ended December 31, 2025, and provided a corporate update.”
Xos, Inc. reported the fourth quarter and full year ended December 31, 2025 results: revenue $5.2 million in revenue in the fourth quarter.
“operating loss of $14.6 million and a non-GAAP operating loss of $6.4 million in Q4 2024 — a 27.1% improvement in non-GAAP operating loss. • Xos delivered 34 units and generated $5.2 million in revenue in the fourth quarter, compared to 51 units and $11.5 million in Q4 2024 as the Company began shifting focus and allocating resources to powertrain production as”
Guerrilla RF, Inc. reported the year ended December 31, 2025 results: revenue $22.7 million, EPS $0.67.
“Full Year 2025 Highlights Management believes these full year 2025 results demonstrate a clear transition towards profitability, with substantial operating loss reduction, improved margins, and significantly lower cash burn. ● Revenue increased 13% to $22.7 million, reflecting continued product momentum. ● Gross profit grew 16% to $14.9 million, outpacing revenue as a result of changes in product price and mix. ● Gross profit margin expanded to 65.3%, up 160 basis points, demonstrating improving product mix and scale benefits. Significant Operating Leverage and Loss Reduction ● Operating loss improved by $4.1 million to $4.7 million, at 47% year over year reduction. ● Total operating expenses declined by $2.1 million, or 10%, driven by disciplined cost management. Dramatic Improvement in Cash Efficiency ● Cash used in operations reduced to $1.4 million, compared to $6.7 million in 2024, representing an approximately 79% improvement. ● Improvement driven by stronger margins, lower opera”
Guerrilla RF, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $6.7 million.
“Fourth Quarter 2025 Highlights ● Revenue increased 53% year over year to $6.7 million, a new quarterly record ● Gross profit rose 68% year over year to $4.5 million. ● Gross profit margin increased to 66.4%, up 600 basis points year over year. ● Operating expenses declined 24% year over year to $4.4 million, reflecting the efficiency actions the Company executed during the year. ● Achieved operating income of approximately $55 thousand, a significant improvement compared to an operating loss of $3.1 million in the prior year quarter. ● Generated positive operating cash flow of $1.1 million, marking a significant financial milestone.”
P3 Health Partners Inc. reported financial results for the fourth quarter ended December 31, 2025.
“P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its financial results for the fourth quarter and full year ended December 31, 2025, and provided 2026 guidance.”
P3 Health Partners Inc. reported financial results for the year ended December 31, 2025.
“On March 26, 2026, P3 Health Partners Inc. (the “Company”) announced its financial results for the year ended December 31, 2025.”
Dermata Therapeutics, Inc. reported financial results for year ended December 31, 2025.
“Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025”
Rani Therapeutics Holdings, Inc. reported fourth quarter and year ended December 31, 2025 results: revenue $1.5 million.
“to the Chugai agreement, to be sufficient to fund its operations into the fourth quarter of 2027. • Contract revenue for the three and twelve months ended December 31, 2025 were $1.5 million and $1.6 million, respectively. Of this, $1.5 million was attributed to a License and Collaboration Agreement and $0.1 million was attributed to evaluation services performed for”
Southland Holdings, Inc. reported for the quarter and year ended December 31, 2025 results: revenue Revenue of $104.0 million for the quarter ended December 31, 2025, net income Net loss attributable to stockholders of $216.4 million, or $(4.00) per share for the quarter ended December 31, 2025, EPS $(4.00).
“Revenue of $104.0 million for the quarter ended December 31, 2025, compared to $267.3 million for the quarter ended December 31, 2024.”
Worthington Steel, Inc. reported the three months ended February 28, 2026 (the third quarter of fiscal 2026) results: revenue $769.8 million, net income $10.4 million, EPS $0.20.
“financial results for the fiscal 2026 third quarter ended February 28, 2026. Third Quarter Highlights (all comparisons to the third quarter of fiscal 2025) : • Net sales of $769.8 million increased 12% compared to $687.4 million. • Operating income of $3.1 million compared to $18.3 million. • Net earnings attributable to controlling interest of $10.4 million”
Kyverna Therapeutics, Inc. reported financial results for fourth quarter and full year ended December 31, 2025.
“Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results”
Upstream Bio, Inc. reported financial results for the quarter and year ended December 31, 2025.
“On March 26, 2026, Upstream Bio, Inc. (the “Company”) announced its financial results and business highlights for the quarter and year ended December 31, 2025.”
Newsmax Inc. reported financial results for three months and full year ended December 31, 2025.
“On March 26, 2026, Newsmax Inc. (the "Company") issued a press release announcing its results of operations for the three months and full year ended December 31, 2025.”
Lumexa Imaging Holdings, Inc. updated its the quarter and year ended December 31, 2025 guidance (reaffirmed).
“On March 26, 2026, Lumexa Imaging Holdings, Inc. (the “Company”) issued a press release announcing certain preliminary financial information for the quarter and year ended December 31, 2025.”
COMMERCIAL METALS Co reported financial results for second quarter of fiscal year 2026.
“On March 26, 2026, CMC issued a press release announcing its financial results for the second quarter of fiscal year 2026. A copy of the press release is attached hereto as Exhibit 99.1.”
DIXIE GROUP INC reported fiscal year 2025 results: revenue $257,429,000, net income net loss of $7,615,000, EPS $0.52 per diluted share.
“For the fiscal year 2025, net sales for the Company were $257,429,000 or 2.9% below the net sales of $265,026,000 in the fiscal year 2024. The net loss from continuing operations on the year was $7,275,000 in 2025, or $0.50 per diluted share, compared to a net loss of $12,210,000, or $0.83 per diluted share, in 2024. The net loss on the year was $7,615,000, or $0.52 per diluted share, compared to a net loss of $13,000,000, or $0.88 per diluted share, in 2024.”
DIXIE GROUP INC reported the fourth quarter and the year ended December 27, 2025 results: revenue $63,487,000, net income net loss of $3,001,000.
“The Dixie Group, Inc. (OTCQB: DXYN) today reported financial results for the fourth quarter and the year ended December 27, 2025. In the fourth quarter of 2025, net sales were $63,487,000 or 1.4% below the net sales in the fourth quarter of 2024 at $64,338,000. The net loss for the fourth quarter of 2025 was $3,001,000. This compares to a net loss of $7,198,000 in the fourth quarter of 2024. For the fiscal year 2025, net sales for the Company were $257,429,000 or 2.9% below the net sales of $265,026,000 in the fiscal year 2024. The net loss from continuing operations on the year was $7,275,000 in 2025, or $0.50 per diluted share, compared to a net loss of $12,210,000, or $0.83 per diluted share, in 2024. The net loss on the year was $7,615,000, or $0.52 per diluted share, compared to a net loss of $13,000,000, or $0.88 per diluted share, in 2024.”
FULLER H B CO reported fiscal 2026 results: EPS $4.55 to $4.90. Guidance raised.
“As a result of our year-to-date performance and current macroeconomic conditions, we are updating our previously communicated financial guidance for the following items for fiscal 2026: ■ Net revenue for fiscal 2026 is now expected to be up mid-single digits; organic revenue is now expected to be up low-single digits and the impact from foreign exchange is now expected to be positive 1% to 2%; ■ Adjusted EBITDA for fiscal 2026 is now expected to be in the range of $645 million to $675 million; ■ Adjusted EPS (diluted) is now expected to be in the range of $4.55 to $4.90;”
FULLER H B CO reported the first quarter ended February 28, 2026 results: revenue $771 million, net income $21 million, EPS $0.38. Guidance raised.
“– H.B. Fuller Company (NYSE: FUL) today reported financial results for its first quarter that ended February 28, 2026. First Quarter 2026 Noteworthy Items: ■ Net revenue was $771 million; organic revenue was down 6.6% year-on-year; ■ Gross margin was 30.6%; adjusted gross margin of 31.3% increased 170 basis points year-on-year driven by restructuring savings from”
STIFEL FINANCIAL CORP reported preliminary financial results for February 28, 2026.
“Stifel Financial Corp. (NYSE: SF) today reported selected operating results for February 28, 2026, to provide timely information to investors on certain key performance metrics.”
NORTECH SYSTEMS INC reported the fourth quarter ended December 31, 2025 results: revenue $30.3 million, net income $897 thousand, EPS $0.32 per basic share.
“Nortech Systems Incorporated (Nasdaq: NSYS) (“Nortech” or the “Company”), a leading provider of engineering and manufacturing solutions for complex electromedical and electromechanical products serving the medical imaging, medical device, industrial, and aerospace & defense markets, reported financial results for the fourth quarter ended December 31, 2025. 2025 Q4 Highlights: ● Net sales of $30.3 million in Q4 2025 vs. $28.6 million in Q4 2024 ● Net income of $897 thousand, or $0.32 per basic share in Q4 2025 vs. $(1,478) thousand, or $(0.54) per basic share in Q4 2024”
REX AMERICAN RESOURCES Corp reported fourth quarter of fiscal 2025 (Q4 2025) results: revenue $158.0 million, net income $43.7 million, EPS $1.32.
“per share in Full Fiscal Year ‘25 § Reported gross profit of $28.9 million for fourth quarter and $93.7 million for Full Fiscal Year ‘25 § Reported net sales and revenue of $158.0 million for fourth quarter and $650.5 million for Full Fiscal Year ’25 § Reported consolidated ethanol sales volumes of 70.1 million gallons for fourth quarter and 290.0 million gallons”
REX AMERICAN RESOURCES Corp reported Full Fiscal Year 2025 results: revenue $650.5 million, net income $83.0 million, EPS $2.50.
“§ Reported gross profit of $28.9 million for fourth quarter and $93.7 million for Full Fiscal Year ‘25 § Reported net sales and revenue of $158.0 million for fourth quarter and $650.5 million for Full Fiscal Year ’25 § Reported consolidated ethanol sales volumes of 70.1 million gallons for fourth quarter and 290.0 million gallons for Full Fiscal Year ’25 Dayton, OH -”
OXFORD INDUSTRIES INC updated its the fourth quarter and fiscal year ended January 31, 2026 guidance (initiated).
“On March 26, 2026, Oxford Industries, Inc. issued a press release announcing, among other things, its financial results for the fourth quarter and fiscal year ended January 31, 2026.”
INTERLINK ELECTRONICS INC reported the fourth quarter ended December 31, 2025 results: revenue $2,853, net income $(574), EPS $(0.04).
“Results (Amounts in thousands except per share data and percentages) Three Months Ended December 31, Year Ended December 31, 2025 2024 $ ∆ % ∆ 2025 2024 $ ∆ % ∆ Revenue $ 2,853 $ 2,986 $ (133 ) (4.5 )% $ 11,890 $ 11,679 $ 211 1.8 % Gross profit $ 905 $ 1,183 $ (278 ) (23.5 )% $ 4,630 $ 4,846 $ (216 ) (4.5 )% Gross margin 31.7 % 39.6 % 38.9 % 41.5 %”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.